

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088307 A2

- (51) International Patent Classification⁷: C12N
- (21) International Application Number: PCT/US02/11854
- (22) International Filing Date: 26 April 2002 (26.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/287,653 30 April 2001 (30.04.2001) US
- (71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HINTON, Paul, Robert** [US/US]; 321 Dunsmuir Terrace, Number 4, Sunnyvale, CA 94086 (US). **VASQUEZ, Maximilano** [CR/US]; 3818 Louis Road, Palo Alto, CA 94303 (US).
- (74) Agents: **KELLEY, James, J. et al.**; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMANIZED ANTIBODIES

(57) Abstract: Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.

WO 02/088307 A2

HUMANIZED ANTIBODIES

This application claims priority of US 60/287,653, filed 2001 April 30, the entire contents of which are incorporated herein by reference.

The invention relates to humanized antibodies useful for treating and preventing human diseases associated with amyloid β ($A\beta$), such as Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. Mouse monoclonal antibody 10D5 was raised by immunizing mice with human $A\beta$ 1-28, and has been widely used in analytical methods [*J. Neuropathol. Exper. Neurology* 51:76-83 (1992); *Nature* 359:325-327 (1992); *Neuroscience Lett.* 172:122-124 (1994); *Biochem. Biophys. Res. Commun.* 200:1598-1603 (1994); *J. Neuropathol. Exper. Neurology* 53:377-383 (1994); *Annals Neurology* 37:512-518 (1995); *Annals Neurology* 41:809-813 (1997); *J. Neuroimmunol.* 88:85-90 (1998); *J. Neuroimmunol.* 95:136-142 (1999)]. 10D5 has been shown to bind to the N-terminal region of $A\beta$ and has affinity of approximately 43 pM for aggregated $A\beta$.

After 10D5 was administered to a group of 8.5 to 10.5 month-old heterozygous, transgenic PDAPP mice (APP^{V717F}) at a weekly intraperitoneal dose of about 10 mg/kg for six months, the mice had significantly reduced levels of $A\beta$ 1-42 in brain cortex. However, the 10D5 group did not have a significant reduction of total $A\beta$ in any tissue, nor of $A\beta$ 1-42 in hippocampus or cerebellum [Bard, F., *et al.*, *Nature Med.* 6:916-919 (2000); WO 00/72876 and WO 00/72880, 7 December, 2000]. It was asserted that amyloid plaques in the 10D5 group also reduced in number and appearance, with some evidence of cell-associated immunoreactivity.

Another study in WO 00/72876 and WO 00/72880 reported that administration of 10D5 to older mice for six months caused a significant reduction in amyloid β plaque burden. It was asserted that the antibody gained access to the central nervous system in sufficient amounts to "decorate" β -amyloid plaques. Finally, it was stated that mouse 10D5 induces phagocytosis of amyloid plaques in *in vitro* studies.

Methods for administering aggregated $A\beta$ 1-42 to provoke an immunologic response and reduced amyloid deposits are described in PCT publication WO99/27944, published 10 June 1999. The description postulates that full-length aggregated $A\beta$ peptide would be a useful immunogen. The application also indicates that antibodies that bind to $A\beta$ peptide could be used as alternate therapeutic agents. However, this appears

to be speculation since the supporting data reflect protocols that involve active immunization using, for example, A β 1-42.

WO 99/60024, published 25 November 1999, is directed to methods for amyloid removal using anti-amyloid antibodies. The mechanism, however, is stated to utilize the ability of anti-A β antibodies to bind to pre-formed amyloid deposits (i.e. plaques) and result in subsequent microglial clearance of localized plaques. This mechanism was not proved *in vivo*. This publication further states that to be effective against A β plaques, anti-A β antibodies must be delivered directly to the brain, because antibodies cannot cross the blood brain barrier.

10 Queen, *et al.* describe methods of humanizing antibodies [*e.g.*, US Patent Nos. 5,585,089, 5,693,761, 5,693,762, 6,180,370].

Humanized forms of 10D5 are needed for use in humans having Down's syndrome, or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy (CAA). However, it is not known whether 10D5 can be humanized so that the humanized antibody retained the binding properties of the mouse antibody.

15

Summary of the Invention

This invention provides humanized forms of 10D5. These humanized antibodies have binding properties (affinity and epitope location) that are approximately the same as those of the mouse 10D5 antibody. The invention includes antibodies, single chain antibodies, and fragments thereof. The invention includes antibodies wherein the CDR are those of mouse monoclonal antibody 10D5 (sequences SEQ ID NO:1 through SEQ ID NO:6) and wherein the antibodies retain approximately the binding properties of the mouse antibody and have *in vitro* and *in vivo* properties functionally equivalent to the mouse antibody. In another aspect, this invention provides humanized antibodies and fragments thereof, wherein the variable regions have sequences comprising the CDR from mouse antibody 10D5 and specific human framework sequences (sequences SEQ ID NO:7 - SEQ ID NO:10), wherein the antibodies retain approximately the binding properties of the mouse antibody and have *in vitro* and *in vivo* properties functionally equivalent to the mouse antibody 10D5. In another aspect, this invention provides humanized antibodies and fragments thereof, wherein the light chain is SEQ ID NO:11 and the heavy chain is SEQ ID NO:12.

20

25

30

Also part of the invention are polynucleotide sequences that encode the humanized antibodies or fragments thereof disclosed above, vectors comprising the polynucleotide sequences encoding the humanized antibodies or fragments thereof, host cells transformed with the vectors or incorporating the polynucleotides that express the humanized
5 antibodies or fragments thereof, pharmaceutical formulations of the humanized antibodies and fragments thereof disclosed herein, and methods of making and using the same.

Such humanized antibodies and fragments thereof are useful for, among other things, treating and preventing diseases and conditions characterized by A β plaques or A β toxicity in the brain, such as Alzheimer's disease, Down's syndrome, and cerebral
10 amyloid angiopathy in humans.

The invention also includes use of a humanized antibody of the present invention for the manufacture of a medicament, including prolonged expression of recombinant sequences of the antibody or antibody fragment in human tissues, for treating, preventing, or reversing Alzheimer's disease, Down's syndrome, or cerebral amyloid angiopathy, or
15 to inhibit the formation of amyloid plaques or the effects of toxic soluble A β species in humans.

Detailed Description of the Invention

We have surprisingly found that humanized antibodies, wherein the CDRs originate from mouse monoclonal antibody 10D5 and the framework and other portions
20 of the antibodies originate from a human germ line, bind A β 1-40 and A β 1-42 with at least the affinity with which mouse 10D5 binds A β . Thus, we have a reasonable basis for believing that humanized antibodies of this specificity, modified to reduce their immunogenicity by converting them to a humanized form, offer the opportunity to treat, both prophylactically and therapeutically, conditions in humans that are associated with
25 formation of beta-amyloid plaques. These conditions include, as noted above, pre-clinical and clinical Alzheimer's, Down's syndrome, and pre-clinical and clinical cerebral amyloid angiopathy.

As used herein, the word "treat" includes therapeutic treatment, where a condition to be treated is already known to be present and prophylaxis - *i.e.*, prevention of, or
30 amelioration of, the possible future onset of a condition.

By "antibody" is meant a monoclonal antibody *per se*, or an immunologically effective fragment thereof, such as an Fab, Fab', or F(ab')₂ fragment thereof. In some contexts, herein, fragments will be mentioned specifically for emphasis; nevertheless, it will be understood that regardless of whether fragments are specified, the term "antibody" includes such fragments as well as single-chain forms. As long as the protein retains the ability specifically to bind its intended target, it is included within the term "antibody." Also included within the definition "antibody" are single chain forms. Preferably, but not necessarily, the antibodies useful in the invention are produced recombinantly. Antibodies may or may not be glycosylated, though glycosylated antibodies are preferred. Antibodies are properly cross-linked via disulfide bonds, as is well known.

The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

Light chains are classified as kappa and lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 3 or more amino acids.

The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites. The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N- terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with well known conventions [Kabat, et al., "Sequences of Proteins of Immunological Interest" National Institutes of Health, Bethesda, Md., 1987 and 1991; Chothia, et al., J. Mol. Biol. 196:901-917 (1987); Chothia, et al., Nature 342:878-883 (1989)].

By "humanized antibody" is meant an antibody that is composed partially or fully of amino acid sequences derived from a human antibody germline by altering the sequence of an antibody having non-human complementarity determining regions (CDR). A humanized immunoglobulin does not encompass a chimeric antibody, having a mouse
5 variable region and a human constant region. However, the variable region of the antibody and even the CDR are humanized by techniques that are by now well known in the art. The framework regions of the variable regions are substituted by the corresponding human framework regions leaving the non-human CDR substantially intact. As mentioned above, it is sufficient for use in the methods of the invention, to
10 employ an immunologically specific fragment of the antibody, including fragments representing single chain forms.

Humanized antibodies have at least three potential advantages over non-human and chimeric antibodies for use in human therapy:

1) because the effector portion is human, it may interact better with the other parts
15 of the human immune system (e.g., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC).

2) The human immune system should not recognize the framework or C region of the humanized antibody as foreign, and therefore the antibody response against such an
20 injected antibody should be less than against a totally foreign non-human antibody or a partially foreign chimeric antibody.

3) Injected non-human antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of human antibodies. Injected humanized antibodies will have a half-life essentially identical to naturally occurring
25 human antibodies, allowing smaller and less frequent doses to be given.

The design of humanized immunoglobulins may be carried out as follows. As to the human framework region, a framework or variable region amino acid sequence of a CDR-providing non-human immunoglobulin is compared with corresponding sequences in a human immunoglobulin variable region sequence collection, and a sequence having a
30 high percentage of identical amino acids is selected. When an amino acid falls under the following category, the framework amino acid of a human immunoglobulin to be used

(acceptor immunoglobulin) is replaced by a framework amino acid from a CDR-providing non-human immunoglobulin (donor immunoglobulin):

- (a) the amino acid in the human framework region of the acceptor immunoglobulin is unusual for human immunoglobulin at that position, whereas the corresponding amino acid in the donor immunoglobulin is typical for human immunoglobulin at that position;
- (b) the position of the amino acid is immediately adjacent to one of the CDRs; or
- (c) any side chain atom of a framework amino acid is within about 5-6 angstroms (center-to-center) of any atom of a CDR amino acid in a three dimensional immunoglobulin model [Queen, *et al.*, Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989), and Co, *et al.*, Proc. Natl. Acad. Sci. USA 88, 2869 (1991)]. When each of the amino acid in the human framework region of the acceptor immunoglobulin and a corresponding amino acid in the donor immunoglobulin is unusual for human immunoglobulin at that position, such an amino acid is replaced by an amino acid typical for human immunoglobulin at that position.

A preferred humanized antibody is a humanized form of mouse antibody 10D5.

The CDRs of humanized 10D5 have the following amino acid sequences:

light chain CDR1:

1 5 10 15
20 Arg Ser Ser Gln Asn Ile Ile His Ser Asn Gly Asn Thr Tyr Leu Glu
(SEQ ID NO:1)

light chain CDR2:

1 5
25 Lys Val Ser Asn Arg Phe Ser (SEQ ID NO:2)

light chain CDR3:

1 5
30 Phe Gln Gly Ser His Val Pro Leu Thr (SEQ ID NO:3)

heavy chain CDR1:

1 5
Thr Ser Gly Met Gly Val Ser (SEQ ID NO:4)

35 heavy chain CDR2:

1 5 10 15
His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser
(SEQ ID NO:5)

40 and, heavy chain CDR3:

1 5 10
Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr (SEQ ID NO:6).

A preferred light chain variable region of a humanized antibody of the present invention has the following amino acid sequence, in which the framework originated from human germline Vk segment DPK18 and J segment Jk4:

```

5      1           5           10           15
   Asp Val Xaa Met Thr Gln Xaa Pro Leu Ser Leu Pro Val Xaa Leu Gly
      20           25           30
10    Xaa Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Xaa His Ser
      35           40           45
   Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      50           55           60
15    Pro Xaa Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      65           70           75           80
   Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
20    Ser Arg Val      85           90           95
   Ser Arg Val Glu Ala Glu Asp Xaa Gly Val Tyr Tyr Cys Phe Gln Gly
      100          105          110
25    Ser His Val Pro Leu Thr Phe Gly Xaa Gly Thr Lys Xaa Glu Ile Lys
   Arg
                                     (SEQ ID NO:7) .

```

wherein:

- Xaa at position 3 is Val or Leu;
- 30 Xaa at position 7 is Ser or Thr;
- Xaa at position 14 is Thr or Ser;
- Xaa at position 17 is Gln, Asp, or Asn;
- Xaa at position 30 is Ile or Val;
- Xaa at position 50 is Arg or Lys;
- 35 Xaa at position 88 is Val or Leu;
- Xaa at position 105 is Gly or Ala; and
- Xaa at position 109 is Val or Leu.

A preferred heavy chain variable region of a humanized antibody of the present invention has the following amino acid sequence, in which the framework originated from human germline VH segment DP-28 and J segment JH4, with several amino acid substitutions to the consensus amino acids in the same human subgroup to reduce potential immunogenicity:


```

1           5           10           15
Xaa Xaa Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu

5           20           25           30
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser

           35           40           45
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu

10          50           55           60
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Xaa

           65           70           75           80
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Xaa Xaa Gln Val

15          85           90           95
Val Leu Xaa Xaa Thr Xaa Xaa Asp Pro Val Asp Thr Ala Thr Tyr Tyr

           100          105          110
Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr

           115          120
Trp Gly Gln Gly Thr Xaa Val Thr Val Ser Ser (SEQ ID NO:8).

```

25 wherein:

Xaa at position 1 is Gln or Glu;

Xaa at position 2 is Val or Ala;

Xaa at position 64 is Ser or Thr;

Xaa at position 77 is Lys or Arg;

30 Xaa at position 78 is Ser or Thr;

Xaa at position 83 is Thr or Ser;

Xaa at position 84 is Met, Ile, or Leu;

Xaa at position 86 is Asn, Ser, or Thr;

Xaa at position 87 is Met, Val, or Leu; and

35 Xaa at position 118 is Leu or Ser.

A particularly preferred light chain variable region of a humanized antibody of the present invention has the following amino acid sequence, in which the framework originated from human germline Vk segment DPK18 and J segment Jk4:

```

40  1           5           10           15
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly

           20           25           30
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Ile His Ser

45          35           40           45
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser

```

50 55 60
 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 5 65 70 75 80
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 85 90 95
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 10 100 105 110
 Ser His Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 15 Arg (SEQ ID NO:9).

A particularly preferred heavy chain variable region of a humanized antibody of
 20 the present invention has the following amino acid sequence, in which the framework
 originated from human germline VH segment DP-28 and J segment JH4:

1 5 10 15
 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 25 20 25 30
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 35 40 45
 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 30 50 55 60
 Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
 65 70 75 80
 35 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val
 85 90 95
 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 40 100 105 110
 Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr
 115 120
 45 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser (SEQ ID NO:10).

A preferred light chain for a humanized antibody of the present invention has the
 50 amino acid sequence:

1 5 10 15
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 20 25 30
 55 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Ile His Ser

```

      35      40      45
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser

      50      55      60
5  Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

      65      70      75      80
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

10      85      90      95
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly

      100      105      110
Ser His Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

15      115      120      125
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu

      130      135      140
20 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

      145      150      155      160
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln

25      165      170      175
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser

      180      185      190
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu

30      195      200      205
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser

      210      215
35 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO:11).

```

A preferred heavy chain for a humanized antibody of the present invention has the amino acid sequence:

```

40  1      5      10      15
Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu

      20      25      30
45 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser

      35      40      45
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu

      50      55      60
50 Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser

      65      70      75      80
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val

55      85      90      95
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr

      100      105      110
60 Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr

```

115 120 125
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 130 135 140
 5 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
 145 150 155 160
 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
 10 165 170 175
 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 180 185 190
 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
 15 195 200 205
 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
 210 215 220
 20 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
 225 230 235 240
 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 25 245 250 255
 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 260 265 270
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 30 275 280 285
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 290 295 300
 35 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 305 310 315 320
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 40 325 330 335
 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 340 345 350
 45 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 355 360 365
 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 370 375 380
 50 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 385 390 395 400
 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 405 410 415
 55 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 420 425 430
 60 Thr Val Asp Lys Ser Arg Trp Gln Gly Asn Val Phe Ser Cys Ser
 435 440 445
 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

450
Leu Ser Pro Gly Lys

(SEQ. ID NO:12).

5

Other sequences are possible for the light and heavy chains for humanized 10D5. The immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region segments.

10

In another aspect, the present invention is directed to recombinant polynucleotides encoding antibodies which, when expressed, comprise the heavy and light chain CDRs from an antibody of the present invention. Exemplary polynucleotides, which on expression code for the polypeptide chains comprising the heavy and light chain CDRs of monoclonal antibody 10D5 are given herein. Due to codon degeneracy, other polynucleotide sequences can be readily substituted for those sequences. Particularly preferred polynucleotides of the present invention encode antibodies, which when expressed, comprise the CDRs of SEQ ID NO:1 – SEQ ID NO:6, or any of the variable regions of SEQ ID NO:7 – SEQ ID NO:10, or the light and heavy chains of SEQ ID NO:11 and SEQ ID NO:12.

15

20

The polynucleotides will typically further include an expression control polynucleotide sequence operably linked to the humanized immunoglobulin coding sequences, including naturally-associated or heterologous promoter regions. Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host cell line, the host cell is propagated under conditions suitable for expressing the nucleotide sequences, and, as desired, the collection and purification of the light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms may follow.

25

30

The nucleic acid sequences of the present invention capable of ultimately expressing the desired humanized antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e.g., V, J, D, and C regions), using any of a variety of well known

techniques. Joining appropriate genomic and synthetic sequences is a common method of production, but cDNA sequences may also be utilized.

Below is a cDNA sequence (SEQ ID NO:17), from which the light chain having the amino acid sequence of SEQ ID NO:19 may be expressed.

```
5
  ATGAAGTTGCCTGTTAGGCTGTTGGTACTGATGTTCTGGATTCTGCTTCCAGCAGTGAT
  1 -----+-----+-----+-----+-----+-----+-----+ 60
    M K L P V R L L V L M F W I P A S S S D -
10
  GTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACTCTTGGACAGCCAGCCTCCATC
  61 -----+-----+-----+-----+-----+-----+-----+ 120
    V V M T Q S P L S L P V T L G Q P A S I -
15
  TCTTGCAGATCTAGTCAGAACATTATACATAGTAATGGAAACACCTATTTAGAATGGTAC
  121 -----+-----+-----+-----+-----+-----+-----+ 180
    S C R S S Q N I I H S N G N T Y L E W Y -
20
  CTGCAGAAACCAGGCCAGTCTCCAAGGCTCCTGATCTACAAAGTTTCCAACCGATTCTTCT
  181 -----+-----+-----+-----+-----+-----+-----+ 240
    L Q K P G Q S P R L L I Y K V S N R F S -
25
  GGGTCCCAGACAGGTTCAAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGC
  241 -----+-----+-----+-----+-----+-----+-----+ 300
    G V P D R F S G S G S G T D F T L K I S -
30
  AGAGTGGAGGCTGAGGATGTGGGAGTTTATTACTGCTTTCAAGGTTACATGTTCCGCTC
  301 -----+-----+-----+-----+-----+-----+-----+ 360
    R V E A E D V G V Y Y C F Q G S H V P L -
35
  ACTTTCGGCGGAGGGACCAAGGTGGAATAAAACGAACTGTGGCTGCACCATCTGTCTTC
  361 -----+-----+-----+-----+-----+-----+-----+ 420
    T F G G G T K V E I K R T V A A P S V F -
40
  ATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTG
  421 -----+-----+-----+-----+-----+-----+-----+ 480
    I F P P S D E Q L K S G T A S V V C L L -
45
  AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGAAGGTGGATAACGCCCTCCAATCG
  481 -----+-----+-----+-----+-----+-----+-----+ 540
    N N F Y P R E A K V Q W K V D N A L Q S -
50
  GGTAAGTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC
  541 -----+-----+-----+-----+-----+-----+-----+ 600
    G N S Q E S V T E Q D S K D S T Y S L S -
55
  AGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTC
  601 -----+-----+-----+-----+-----+-----+-----+ 660
    S T L T L S K A D Y E K H K V Y A C E V -
60
  ACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT (SEQ ID NO:17)
  661 -----+-----+-----+-----+-----+-----+-----+ 714
    T H Q G L S S P V T K S F N R G E C - (SEQ ID NO:19)
```

Below is a cDNA sequence (SEQ ID NO:18), from which the heavy chain having the amino acid sequence of SEQ ID NO:20 may be expressed.

```

  ATGGACAGGCTTACTTCCTCATTCCTGCTGCTGATTGTCCCTGCATATGTCCTGTCCCAG
  1 -----+-----+-----+-----+-----+-----+-----+ 60
    M D R L T S S F L L L I V P A Y V L S Q -
```

5

10

15

20

25

30

35

40

45

50

55

60

65

61

121

181

241

301

361

421

481

541

601

661

721

781

841

901

961

1021

1081

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

1020

1080

GTACTCTGAAAGAGTCTGGCCCTGTACTGTGAAGCCACCCAGACCTCTACTCTGACT

V T L K E S G P V L V K P T E T L T L T -

TGTACTTTCTCTGGGTTTTCTACTGAGCACTTCTGGTATGGGAGTGAGCTGGATTCTGTCAG

C T F S G F S L S T S G M G V S W I R Q -

CCTCCAGGAAAGGCTCTGGAGTGGCTGGCACACATTACTGGGATGATGACAAGCGCTAT

P P G K A L E W L A H I Y W D D D K R Y -

AACCCATCCCTGAAGAGCGGCTCACAATCTCCAAGGATACCTCCAAAAGCCAGGTAGTC

N P S L K S R L T I S K D T S K S Q V V -

CTCACGATGACCAATATGGACCCTGTAGATACTGCCACATACTACTGTGTTCTGAAGGCC

L T M T N M D P V D T A T Y Y C V R R P -

ATTACTCCGCTACTAGTCGATGCTATGGACTACTGGGGCCAAGGAACCTGGTCACCGTC

I T P V L V D A M D Y W G Q G T L V T V -

TCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCTCCAAGAGCACC

S S A S T K G P S V F P L A P S S K S T -

TCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACG

S G G T A A L G C L V K D Y F P E P V T -

GTGTCTGGAACTCAGGCGCCCTGACCAGCGGCGTGACACCTTCCCGGCTGTCTACAG

V S W N S G A L T S G V H T F P A V L Q -

TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC

S S G L Y S L S S V V T V P S S S L G T -

CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT

Q T Y I C N V N H K P S N T K V D K K V -

GAGCCCAAATCTGTGACAAACTCACACATGCCACCGTGCCAGCACCTGAACTCTTG

E P K S C D K T H T C P P C P A P E L L -

GGGGGACCGTCAGTCTTCCTCTTCCCCCAAACCCAGGACACCTCATGATCTCCCGG

G G P S V F L F P P K P K D T L M I S R -

ACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAGTTTC

T P E V T C V V V V D V S H E D P E V K F -

AACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG

N W Y V D G V V E V H N A K T K P R E E Q -

TACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCTGCACCAGGACTGGCTGAAT

Y N S T Y R V V S V L T V L H Q D W L N -

GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAAAC

G K E Y K C K V S N K A L P A P I E K T -

5
 10
 15
 20
 25

```

    ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCTGCCCCATCCCGG
1081 -----+-----+-----+-----+-----+-----+-----+ 1140
    I S K A K G Q P R E P Q V Y T L P P S R -

    GATGAGCTGACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC
1141 -----+-----+-----+-----+-----+-----+-----+ 1200
    D E L T K N Q V S L T C L V K G F Y P S -

    GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
1201 -----+-----+-----+-----+-----+-----+-----+ 1260
    D I A V E W E S N G Q P E N N Y K T T P -

    CCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGC
1261 -----+-----+-----+-----+-----+-----+-----+ 1320
    P V L D S D G S F F L Y S K L T V D K S -

    AGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC
1321 -----+-----+-----+-----+-----+-----+-----+ 1380
    R W Q Q G N V F S C S V M H E A L H N H -

    TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA (SEQ ID NO:18)
1381 -----+-----+-----+-----+-----+-----+-----+ 1416
    Y T Q K S L S L S P G K - (SEQ ID NO:20)
  
```

The complete sequence of a humanized 10D5 light chain gene with introns
 (located between MluI and BamHI sites, as in pVk-Hu10D5) is shown below (SEQ ID
 NO:15). The nucleotide number indicates its position in pVk-Hu10D5. The V_k and C_k
 exons are translated in single letter code; the dot indicates the translation termination
 codon. The mature light chain starts at the double-underlined aspartic acid (D). The
 intron sequences are in *italic*. The expressed light chain corresponds to SEQ ID NO:11
 when mature.

35
 40
 45
 50
 55

```

    619 ACGCGTCCACCATGAAGTTGCCTGTTAGGCTGTTGGTACTGATGTTCTGGATTCTGCTTCCAGCAGTGATGTTGTGATG
      M K L P V R L L V L M F W I P A S S S D V V M
    699 ACCCAATCTCCACTCTCCCTGCCTGTCACTCTTGGACAGCCAGCCTCCATCTCTTGACAGATCTAGTCAGAACATTATACA
      T Q S P L S L P V T L G Q P A S I S C R S S Q N I I H
    779 TAGTAATGGAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAGGCTCTGATCTACAAAGTTTCCA
      S N G N T Y L E W Y L Q K P G Q S P R L L I Y K V S
    859 ACCGATTTTCTGGGGTCCAGACAGGTTCACTGGCAGTGGATCAGGGACAGATTTCACTCAACTCAGCAGAGTGGAG
      N R F S G V P D R F S G S G S G T D F T L K I S R V E
    939 GCTGAGGATGTGGGAGTTTATTACTGCTTTCAAGGTTACATGTTCCGCTCACTTTCCGGCGGAGGACCAAGGTGGAAT
      A E D V G V Y Y C F Q G S H V P L T F G G G E T K V E I
    1019 AAAACGTAAGTGCACTTTCTTAATCTAGAAATTCTAAACTCTGAGGGGGTCGGATGACGTGGCCATTCTTTGCCTAAAGC
      K R
    1099 ATTGAGTTTACTGCAAGGTCAGAAAAGCATGCAAAGCCCTCAGAATGGCTGCAAAGAGCTCCAACAAAACAATTTAGAAC
    1179 TTTATTAAGGAATAGGGGAAGCTAGGAAGAACTCAAACATCAAGATTTTAAATACGCTTCTTGGTCTCCTTGCTATA
    1259 ATTATCTGGGATAAGCATGCTGTTTCTGTCTGTCCCTAACATGCCCTGTGATTATCCGCAAACAACACCCCAAGGGCA
    1339 GAACTTTGTTACTTAAACACCATCCTGTTTGCTTCTTTCTCAGGAAGTGTGGCTGCACCATCTGTCTTCATCTTCCCGC
      T V A A P S V F I F P
    1419 CATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTA
      P S D E Q L K S G T A S V V C L L N N F Y P R E A K V
    1499 CAGTGGGAAGGTGGATAACGCCCTCCAATCGGGTAAGTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTA
      Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y
    1579 CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCCAAGTCAACCATCAGG
      S L S T L T L S K A D Y E K H K V Y A C E V T H Q
    1659 GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTAGAGGGAGAAGTGGCCCCACCTGCTCCTCAGTTCC
      G L S S P V T K S F N R G E C •
    1739 AGCCTGACCCCTCCCATCCTTTGGCCTCTGACCTTTTTCACAGGGGACCTACCCCTATTGCGGTCTCCAGCTCATC
    1819 TTTACCTCACCCCTCCTCCTCTTGGCTTTAATTATGCTAATGTTGGAGGAGAATGAATAAATAA GTGAATCTTGG
  
```


1899 CACCTGTGGTTTCTCTCTTCTCATTAAATAATTATTATCTGTTGTTTACCAACTACTCAATTTCTCTTATAAGGGAC
1979 TAAATATGTAGTCATCCTAAGGCGCATAACCAATTTATAAAAAATCATCTTCATTTTACCCATCATCCTCTGCAA
2059 GACAGTCTCCCTCAAACCCCAAGCCTTCTGTCTCACAGTCCCCTGGGCCATGGTAGGAGAGACTTGCTTCTTGT
2139 TCCCCTCCTCAGCAAGCCCTCATAGTCTTTTAAAGGGTGACAGGTCTTACAGTCATATATCCTTTGATTCATTTCCCTG
5 2219 AGAATCAACCAAAGCAAATTTTCAAAGAAGAAACCTGCTATAAAGAGAATCATTCATGCAACATGATATAAAATAAC
2299 AACACAATAAAAGCAATTAATAAACAACAATAGGGAAATGTTTAAAGTTCATCATGGTACTTAGACTTAATGGAATGTC
2379 ATGCCTTATTTACATTTTAAACAGGTACTGAGGACTCCTGTCTGCCAAGGGCCGTATTGAGTACTTTCCACAACCTAA
2459 TTTAATCCCACTATACTGTGAGATTAAAAACATTCATTAATAATGTTGCAAAGGTTCTATAAAGCTGAGAGACAAATATA
2539 TTCTATAACTCAGCAATCCCCTTCTAGGATCC (SEQ ID NO:15)

10

The complete sequence of a humanized 10D5 heavy chain gene with introns
(located between MluI and BamHI sites, as in pVg1-Hu10D5) is shown below (SEQ ID
NO:16). The nucleotide number indicates its position in pVg1-Hu10D5. The V_H and C_H
exons are translated in single letter code; the dot indicates the translation termination
codon. The mature heavy chain starts at the double-underlined glutamine (Q). The intron
sequences are in italic. The expressed heavy chain corresponds to SEQ ID NO:12 when
mature.

15

20

25

30

35

40

45

50

55

619 ACGCGTCCACCATGGACAGGCTTACTTCTCTCATTCTGCTGCTGATTGTCCTGCATATGTCTGTCCCAGGTTACTCTG
M D R L T S S F L L L I V P A Y V L S Q = V T L
699 AAAGAGTCTGGCCCTGTACTAGTGAAGCCACCGAGACCCTCACTCTGACTTGTACTTTCTCTGGGTTTCTCACTGAGCAC
K E S G P V L V K P T E T L T L T C T F S G F S L S T
779 TTCTGGTATGGGAGTGAGCTGGATTCTGTCAGCCTCCAGGAAAGGCTCTGGAGTGGCTGGCACACATTACTGGGATGATG
S G M G V S W I R Q P P G K A L E W L A H I V D D
859 ACAAGCGCTATAACCCATCCCTGAAGAGCCGGCTCACAATCTCCAAGGATACCTCCAAAGCCAGGTAGTCTCTCACGATG
D K R Y N P S L K S R L T I S K D T S K S Q V V L T M
939 ACCAATATGAGCCCTGTAGATACTGCCACATACTACTGTGTTTCAAGGCCCATCTACTCCGGTACTAGTCGATGCTATGGA
T N M D P V D T A T Y I C N V N H K P S N T K V D A M D
1019 CTACTGGGGCCAAAGGAACCCCTGGTCACCGTCTCTCAGGTGAGTCTCTCACAACCTCTAGAGCTTTCTGGGGCAGGCCAGG
Y W G Q G T L V T V S S
1099 CCTGACCTTGGCTTTGGGGCAGGGAGGGGGCTAAGGTGAGGCGAGGTGGCGCCAGCCAGGTGCACACCCAATGCCCATGAG
1179 CCCAGACACTGGACGCTGAACCTCGCGGACAGTAAAGAACCCAGGGGCTCTGCGCCCTGGGCCCAGCTCTGTCCACAC
1259 CGCGGTACATGGCACCACCTCTCTTGACGCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCTCTCTCAAGAGC
A S T K G P S V F P L A P S S K S
1339 ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTTGGAACCTCAGG
T S G G T A A L G C L V K D Y F P E P V T V W N S G
1419 CGCCCTGACCAAGCGGCTGCACACCTTCCCGGCTGTCTACAGTCTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCG
A L T S G V H T F P A V L Q S S G L Y S L S S V V T
1499 TGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCAGCAACCAAGGTGGACAGAGAA
V P S S S L G T Q T Y I C N V N H K P S N T K V D K K
1579 GTTGGTGAGAGGCCAGCACAGGGAGGGAGGGTGTCTGCTGGAAGCCAGGCTCAGCGCTCTGCTGGACGCATCCCGGCT
V
1659 ATGCAGCCCCAGTCCAGGGCAGCAAGGCAGGCCCCGTCTGCCTCTTCAACCCGAGGGCTCTGCCCCCCCCACTCATGCTC
1739 AGGGAGAGGGTCTTCTGGCTTTTCCCCAGGCTCTGGGCAGGCACAGGCTAGGTGCCCTAAGCCAGGCTTGCACACAA
1819 AGGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAGGACCTGCCCCTGACCTAAGCCCCACCCAAAGGC
1899 CAAACTCTCCACTCCCTCAGCTCGGACACCTTCTCTCTCCAGATTCCAGTAACTCCCAATCTTCTCTCTGCAGAGCCC
E P
1979 AAATCTTGTGACAAAACCTCACACATGCCACCGTGCCAGGTAAGCCAGCCAGGCTCGCCCTCAGCTCAAGGCGGGA
K S C D K T H T C P P C P
2059 CAGGTGCCCTAGAGTAGCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACACGTCCACCTCCATCTCTTCTCTCAGCA
A
2139 CCTGAACCTCCTGGGGGACCGTCACTCTCTCTTCCCCCAAAACCCCAAGGACACCCCTCATGATCTCCCGGACCCCTGA
P E L L G G P S V F L F P P K P K D T L M I S R T P E
2219 GGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAAGTCAACTGGTACGTGGACGGCGTGGAGGTGC
V T C V V V D V S H E D P E V K F N W Y V D G V E V
2299 ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACGACACGTACCGTGTGGTCAAGCTCCTCACCCTCTGCACCAG
H N A K T K P R E Q Y N S T Y R V V S V L H Q
2379 GACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTTCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAA

D W L N G K E Y K C K V S N K A L P A P I E K T I S K
 2459 AGCCAAAGGTGGGACCCGTGGGGTGGAGGGCCACATGGACAGAGGGCGGCTCGGCCACCCCTGTCCTGAGAGTGACC
 A K
 5 2539 GCTGTACCAACCTCTGTCCCTACAGGGCAGCCCCGAGAACCACAGGTGTACACCCATGCCCCATCCCGGGATGAGCTGAC
 G Q P R E P Q V Y T L P P S R D E L T
 2619 CAAGAACCAGGTACGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
 K N Q V S L T C L V K G F Y P S D I A V E W E S N G
 2699 AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTCTCTACAGCAAGCTCACCGTG
 Q P E N N Y K T T P P V L D S D G S F F L Y S K L T V
 10 2779 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAA
 D K S R W Q Q G N V P S C S V M H E A L H N H Y T Q K
 2859 GAGCCTCTCCCTGTCTCCGGGTAATGAGTGGCAGCGCCGGCAAGCCCCGCTCCCCGGGCTCTCGGGTGGCAGGAGGA
 S L S L S P G K -
 2939 TGCTTGGCAGGTACCCCTGTACATACTTCCCGGGCGCCAGCATGGAAATAAA GCACCCAGCGTGCCTTGGGCCCCCTG
 15 3019 CGAGACTGTGATGGTTCTTTCCACGGGTGAGGCCGAGTCTGAGGCCCTGAGTGGCATGAGGGAGGAGAGCGGGTCCCACT
 3099 GTCCCCACACTGGCCAGGCTGTGCAGGTGTGCCTGGGCCGCTAGGGTGGGGCTCAGCCAGGGGCTGCCCTCGGCAGGG
 3179 TGGGGGATTGGCCAGCGTGGCCCTCCCTCCAGCAGCACCTGCCCTGGGCTGGGGCCAGGGAAGCCCTAGGAGCCCCCTGGG
 3259 GACAGACACACAGCCCTGCCTCTGTAGGAGACTGTCTGTCTGTGAGCGCCCTGTCTCCGACCTCCATGCCCACTCG
 3339 GAGGCATGCTAGTCCATGTGCGTAGGGACAGGCCCTCCCTCACCCATCTACCCCAAGGCATTAACCCCTGGCTGCCCT
 20 3419 GCCCAGCCTCGCACCCGATGGGGACACAACCGACTCCGGGGACATGCACTCTCGGGCCCTGTGGAGGGACTGGTGCAGA
 3499 TGCCACACACACACTCAGCCAGACCCGTTCAACAAACCCCGCACTGAGGTGGCCGGCCACAGGCCACACACACAC
 3579 ACGTGCACGCCTCACACACGGAGCCTCACCCGGGCGAACTGCACAGCACCCAGACCAGAGCAAGTCTCGCACACGTGA
 3659 ACACTCCTCGGACACAGGCCCCACGAGCCCCACGCGCACCTCAAGGCCACGAGCCTCTCGGCAGCTTCTCCACATGC
 3739 TGACCTGCTCAGACAAACCCAGCCCTCTCTACAAGGGTGGCCCTGCAGCCGCCACACACACAGGGGATCACACACC
 25 3819 ACGTACGTCCCTGGCCCTGGCCCACTTCCAGTGGCCCTTCCCTGCAGGATCC (SEQ ID NO:16)

Human constant region DNA sequences can be isolated in accordance with well
 known procedures from a variety of human cells, but preferably from immortalized B-
 cells. Suitable source cells for the polynucleotide sequences and host cells for
 30 immunoglobulin expression and secretion can be obtained from a number of sources well-
 known in the art.

In addition to the humanized immunoglobulins specifically described herein, other
 "substantially homologous" modified immunoglobulins can be readily designed and
 manufactured utilizing various recombinant DNA techniques well known to those skilled
 35 in the art. For example, the framework regions can vary from the native sequences at the
 primary structure level by several amino acid substitutions, terminal and intermediate
 additions and deletions, and the like. Moreover, a variety of different human framework
 regions may be used singly or in combination as a basis for the humanized
 immunoglobulins of the present invention. In general, modifications of the genes may be
 40 readily accomplished by a variety of well-known techniques, such as site-directed
 mutagenesis.

Alternatively, polypeptide fragments comprising only a portion of the primary
 antibody structure may be produced, which fragments possess one or more
 immunoglobulin activities (e.g., complement fixation activity). These polypeptide
 45 fragments may be produced by proteolytic cleavage of intact antibodies by methods well
 known in the art, or by inserting stop codons at the desired locations in vectors using site-

directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce F(ab')₂ fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker.

As stated previously, the polynucleotides will be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences.

E. coli is a prokaryotic host useful particularly for cloning the polynucleotides of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any of a number of well-known promoters may be present, such as the lactose promoter system, a tryptophan (*trp*) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.

Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

In addition to microorganisms, mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention. Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, Syrian Hamster Ovary cell lines, HeLa cells, preferably myeloma cell lines, transformed B-cells, human embryonic kidney cell lines, or hybridomas. Expression vectors for these cells can include expression control sequences, such as an

origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, cytomegalovirus and the like.

The vectors containing the polynucleotide sequences of interest (e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts.

Once expressed, the antibodies can be purified according to standard procedures, including ammonium sulfate precipitation, ion exchange, affinity, reverse phase, hydrophobic interaction column chromatography, gel electrophoresis, and the like. Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically or prophylactically, as directed herein.

The antibodies (including immunologically reactive fragments) are administered to a subject at risk for or exhibiting A β -related symptoms or pathology such as clinical or pre-clinical Alzheimer's disease, Down's syndrome, or clinical or pre-clinical amyloid angiopathy, using standard administration techniques, preferably peripherally (*i.e.* not by administration into the central nervous system) by intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. Although the antibodies may be administered directly into the ventricular system, spinal fluid, or brain parenchyma, and techniques for addressing these locations are well known in the art, it is not necessary to utilize these more difficult procedures. The antibodies of the invention are effective when administered by the more simple techniques that rely on the peripheral circulation system. The advantages of the present invention include the ability of the antibody to exert its beneficial effects even though not provided directly to the central nervous system itself. Indeed, it has been

demonstrated that the amount of antibody that crosses the blood-brain barrier is $\leq 0.1\%$ of plasma levels.

The pharmaceutical compositions for administration are designed to be appropriate for the selected mode of administration, and pharmaceutically acceptable
5 excipients such as, buffers, surfactants, preservatives, solubilizing agents, isotonicity agents, stabilizing agents and the like are used as appropriate. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton PA, latest edition, incorporated herein by reference, provides a compendium of formulation techniques as are generally known to practitioners.

10 The concentration of the humanized antibody in formulations may range from as low as about 0.1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, and so forth, in accordance with the particular mode of administration selected. Thus, a pharmaceutical composition for injection could be made up to contain in 1 mL of phosphate buffered saline from 1 to 100 mg of the
15 humanized antibody of the present invention. The formulation could be sterile filtered after making the formulation, or otherwise made microbiologically acceptable. A typical composition for intravenous infusion could have a volume as much as 250 mL of fluid, such as sterile Ringer's solution, and 1-100 mg per mL, or more in antibody concentration. Therapeutic agents of the invention can be frozen or lyophilized for storage and
20 reconstituted in a suitable sterile carrier prior to use. Lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g. with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies). Dosages may have to be adjusted to compensate. The pH of the formulation will be selected to balance antibody stability (chemical and physical) and comfort to the patient when
25 administered. Generally, pH between 4 and 8 is tolerated.

Although the foregoing methods appear the most convenient and most appropriate for administration of proteins such as humanized antibodies, by suitable adaptation, other techniques for administration, such as transdermal administration and oral administration may be employed provided proper formulation is designed.

30 In addition, it may be desirable to employ controlled release formulations using biodegradable films and matrices, or osmotic mini-pumps, or delivery systems based on dextran beads, alginate, or collagen.

In summary, formulations are available for administering the antibodies of the invention and are well-known in the art and may be chosen from a variety of options.

Typical dosage levels can be optimized using standard clinical techniques and will be dependent on the mode of administration and the condition of the patient.

5 The following examples are intended to illustrate but not to limit the invention.

The examples hereinbelow employ, among others, a murine monoclonal antibody designated "10D5" which was originally prepared by immunization with a peptide composed of residues 1-28 of human A β peptide. As the examples here describe experiments conducted in murine systems, the use of murine monoclonal antibodies is satisfactory. However, in the treatment methods of the invention intended for human use, humanized forms of the antibodies with the immunospecificity corresponding to that of antibody 10D5 are preferred.

Example 1

15 Synthesis of Humanized Antibody 10D5

Cells and antibodies. Mouse myeloma cell line Sp2/0 was obtained from ATCC (Manassas, VA) and maintained in DME medium containing 10% FBS (Cat # SH30071.03, HyClone, Logan, UT) in a 37°C CO₂ incubator. Mouse 10D5 hybridoma cells were first grown in RPMI-1640 medium containing 10% FBS (HyClone), 10 mM HEPES, 2 mM glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 25 μ g/ml gentamicin, and then expanded in serum-free media (Hybridoma SFM, Cat # 12045-076, Life Technologies, Rockville, MD) containing 2% low Ig FBS (Cat # 30151.03, HyClone) to a 1.5 liter volume in roller bottles. Mouse monoclonal antibody 10D5 (Mu10D5) was purified from the culture supernatant by affinity chromatography using a protein-G Sepharose column. Biotinylated Mu10D5 was prepared using EZ-Link Sulfo-NHS-LC-LC-Biotin (Cat # 21338ZZ, Pierce, Rockford, IL).

Cloning of variable region cDNAs. Total RNA was extracted from approximately 10⁷ hybridoma cells using TRIzol reagent (Cat. # 15596-026, Life Technologies) and poly(A)⁺ RNA was isolated with the PolyAtract mRNA Isolation System (Cat. # Z5310, Promega, Madison, WI) according to the suppliers' protocols. Double-stranded cDNA was synthesized using the SMARTTMRACE cDNA Amplification Kit (Cat. # K1811-1, Clontech, Palo Alto, CA) following the supplier's protocol. The variable region cDNAs

for the light and heavy chains were amplified by polymerase chain reaction (PCR) using 3' primers that anneal respectively to the mouse kappa and gamma chain constant regions, and a 5' universal primer provided in the SMARTTMRACE cDNA Amplification Kit. For VL PCR, the 3' primer has the sequence:

5

5' -TATAGAGCTCAAGCTTGGATGGTGGGAAGATGGATACAGTTGGTGC-3'

[SEO ID NO:13]

with residues 17- 46 hybridizing to the mouse Ck region. For VH PCR, the 3' primers
10 have the degenerate sequences:

5' - TATAGAGCTCAAGCTTCCAGTGGATAGACCGATGGGGCTGTCGTTTGGC - 3'

15 [SEQ ID NO:14]

with residues 17 - 50 hybridizing to mouse gamma chain CH1. The VL and VH cDNAs were subcloned into pCR4Blunt-TOPO vector (Cat. # 45-0031, Invitrogen, Carlsbad, CA) for sequence determination. DNA sequencing was carried out by PCR cycle sequencing reactions with fluorescent dideoxy chain terminators (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. The sequencing reactions were analyzed on a Model 377 DNA Sequencer (Applied Biosystems).

Construction of humanized 10D5 (Hu10D5) variable regions. Humanization of the mouse antibody V regions was carried out as outlined by Queen et al., 1989, *op. Cit.* The human V region framework used as acceptor for Mu10D5 CDRs was chosen based on sequence homology. The computer programs ABMOD and ENCAD [Levitt, M., J. Mol. Biol. 168:595-620 (1983)] were used to construct a molecular model of the variable regions. Amino acids in the humanized V regions that were predicted to have contact with CDRs were substituted with the corresponding residues of Mu10D5. This was done at residue 98 in the heavy chain and at residues 41 and 51 in the light chain. The amino acids in the humanized V region that were found to be rare in the same V-region subgroup were changed to the consensus amino acids to eliminate potential immunogenicity. This was done at residues 42 and 44 in the light chain and at residue 24 in the heavy chain.

The light and heavy chain variable region genes were constructed and amplified using eight overlapping synthetic oligonucleotides ranging in length from approximately 65 to 80 bases [He, X. Y., et al., J. Immunol. 160: 1029-1035 (1998)]. The oligonucleotides were annealed pairwise and extended with the Klenow fragment of DNA polymerase I, yielding four double-stranded fragments. The resulting fragments were denatured, annealed pairwise, and extended with Klenow, yielding two fragments. These fragments were denatured, annealed pairwise, and extended once again, yielding a full-length gene. The resulting product was amplified by PCR using the Expand High Fidelity PCR System (Cat. # 1 732 650, Roche Molecular Biochemicals, Indianapolis, IN). The PCR-amplified fragments were gel-purified and cloned into pCR4Blunt-TOPO vector. After sequence confirmation, the VL and VH genes were digested with MfuI and XbaI, gel-purified, and subcloned respectively into vectors for expression of light and heavy chains to make pVk-Hu10D5 and pVg1-Hu10D5 [Co, M. S., et al., J. Immunol. 148:1149-1154 (1992)]. The mature humanized 10D5 antibody expressed from these plasmids has the light chain of SEQ ID NO:11 and the heavy chain of SEQ ID NO:12.

Stable transfection. Stable transfection into mouse myeloma cell line Sp2/0 was accomplished by electroporation using a Gene Pulser apparatus (BioRad, Hercules, CA) at 360 V and 25 μ F as described (Co, et al., 1992, *op. cit.*). Before transfection, pVk-Hu10D5 and pVg1-Hu10D5 plasmid DNAs were linearized using FspI. Approximately 10^7 Sp2/0 cells were transfected with 20 μ g of pVk-Hu10D5 and 40 μ g of pVg1-Hu10D5. The transfected cells were suspended in DME medium containing 10% FBS and plated

into several 96-well plates. After 48 hr, selection media (DME medium containing 10% FBS, HT media supplement, 0.3 mg/ml xanthine and 1 µg/ml mycophenolic acid) was applied. Approximately 10 days after the initiation of the selection, culture supernatants were assayed for antibody production by ELISA as shown below. High yielding clones were expanded in DME medium containing 10% FBS and further analyzed for antibody expression. Selected clones were then adapted to growth in Hybridoma SFM.

Measurement of antibody expression by ELISA. Wells of a 96-well ELISA plate (Nunc-Immuno plate, Cat # 439454, NalgeNunc, Naperville, IL) were coated with 100 µl of 1 µg/ml goat anti-human IgG, Fc γ fragment specific, polyclonal antibodies (Cat. # 109-005-098, Jackson ImmunoResearch, West Grove, PA) in 0.2 M sodium carbonate-bicarbonate buffer (pH 9.4) overnight at 4°C. After washing with Washing Buffer (PBS containing 0.1% Tween 20), wells were blocked with 400 µl of Superblock Blocking Buffer (Cat # 37535, Pierce) for 30 min and then washed with Washing Buffer. Samples containing Hu10D5 were appropriately diluted in ELISA Buffer (PBS containing 1% BSA and 0.1% Tween 20) and applied to ELISA plates (100 µl per well). As a standard, humanized anti-CD33 IgG1 monoclonal antibody HuM195 (Co, *et al.*, 1992, *op. cit.*) was used. The ELISA plate was incubated for 2 hr at room temperature and the wells were washed with Washing Buffer. Then, 100 µl of 1/1,000-diluted HRP-conjugated goat anti-human kappa polyclonal antibodies (Cat # 1050-05, Southern Biotechnology, Birmingham, AL) in ELISA Buffer was applied to each well. After incubating for 1 hr at room temperature and washing with Washing Buffer, 100 µl of ABTS substrate (Cat #s 507602 and 506502, Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added to each well. Color development was stopped by adding 100 µl of 2% oxalic acid per well. Absorbance was read at 415 nm using an OPTImax microplate reader (Molecular Devices, Menlo Park, CA).

Purification of Hu10D5. One of the high Hu10D5-expressing Sp2/0 stable transfectants (clone #1) was adapted to growth in Hybridoma SFM and expanded to 2 liters in roller bottles. Spent culture supernatant was harvested when cell viability reached 10% or below and loaded onto a protein-A Sepharose column. The column was washed with PBS before the antibody was eluted with 0.1 M glycine-HCl (pH 2.8), 0.1 M NaCl. The eluted protein was dialyzed against 3 changes of 2 liters of PBS and filtered through a 0.2 µm filter prior to storage at 4°C. Antibody concentration was determined

by measuring absorbance at 280 nm ($1 \text{ mg/ml} = 1.4 A_{280}$). SDS-PAGE in Tris-glycine buffer was performed according to standard procedures on a 4-20% gradient gel (Cat # EC6025, Novex, San Diego, CA). Purified humanized 10D5 antibody is reduced and run on an SDS- PAGE gel. The whole antibody shows two bands of approximate molecular weights 25 kDa and 50 kDa. These results are consistent with the molecular weights of the light chain and heavy chain, or with the molecular weight of the chain(s) comprising a fragment, calculated from their amino acid compositions.

Example 2

In vitro binding properties of humanized 10D5 antibody

The binding efficacy of humanized 10D5 antibody, synthesized and purified as described above, was compared with the mouse 10D5 antibody using biotinylated mouse 10D5 antibody in a comparative ELISA. Wells of a 96-well ELISA plate (Nunc-Immuno plate, Cat # 439454, NalgeNunc) were coated with 100 μl of β -amyloid peptide (1-42) in 0.2 M sodium carbonate/bicarbonate buffer (pH 9.4) (1 $\mu\text{g/mL}$) overnight at 4°C.

After washing the wells with phosphate buffered saline (PBS) containing 0.1% Tween 20 (Washing Buffer) using an ELISA plate washer, the wells were blocked by adding 300 μL of SuperBlock reagent (Pierce) per well. After 30 minutes of blocking, the wells were washed with Washing Buffer and excess liquid was removed.

A mixture of biotinylated Mu10D5 (0.4 $\mu\text{g/ml}$ final concentration) and competitor antibody (Mu10D5 or Hu10D5; starting at 1000 $\mu\text{g/ml}$ final concentration and serial 3-fold dilutions) in ELISA Buffer were added in triplicate in a final volume of 100 μl per well. As a no-competitor control, 100 μl of 0.4 $\mu\text{g/ml}$ biotinylated Mu10D5 was added. As a background control, 100 μl of ELISA Buffer was added. The ELISA plate was incubated at room temperature for 90 min. After washing the wells with Washing Buffer, 100 μl of 10 $\mu\text{g/ml}$ HRP-conjugated streptavidin (Cat # 21124, Pierce) was added to each well. The plate was incubated at room temperature for 30 min and washed with Washing Buffer. For color development, 100 $\mu\text{l/well}$ of ABTS Peroxidase Substrate (Kirkegaard & Perry Laboratories) was added. Color development was stopped by adding 100 $\mu\text{l/well}$ of 2% oxalic acid. Absorbance was read at 415 nm. The absorbances were plotted against the log of the competitor concentration, curves were fit to the data points (using Prism) and the IC50 was determined for each antibody using methods well-known in the art.

The mean IC₅₀ for mouse 10D5 was 23.4 µg/mL (three separate experiments, standard deviation = 5.5 µg/mL) and for humanized 10D5 was 49.1 µg/mL (three separate experiments, standard deviation = 11.8 µg/mL). A second set of three experiments was carried out, essentially as described above, and the mean IC₅₀ for mouse 10D5 was
5 determined to be 20 µg/mL (SD = 1 µg/mL) and for humanized 10D5, the IC₅₀ was determined to be 16 µg/mL (SD = 0.6 µg/mL). On the basis of these results, we conclude that humanized 10D5 has binding properties that are very similar to those of the mouse antibody 10D5. Therefore, we expect that humanized 10D5 has very similar *in vitro* and *in vivo* activities compared with mouse 10D5 and will exhibit in humans the same effects
10 demonstrated with mouse 10D5 in mice.

Example 3

In vitro binding properties of mouse and humanized antibodies 10D5

Antibody affinity ($KD = K_d / K_a$) was determined using a BIAcore biosensor 2000
15 and data analyzed with BIAevaluation (v. 3.1) software. A capture antibody (rabbit anti-mouse Ig or anti-human Ig) was coupled via free amine groups to carboxyl groups on flow cell 2 of a biosensor chip (CM5) using N-ethyl-N-dimethylaminopropyl carbodiimide and N-hydroxysuccinimide (EDC/NHS). A non-specific rabbit IgG was coupled to flow cell 1 as a background control. Monoclonal antibodies were captured to yield 300 resonance
20 units (RU). Amyloid-beta 1-40 or 1-42 (Biosource International, Inc.) was then flowed over the chip at decreasing concentrations (1000 to 0.1 times KD). To regenerate the chip, bound anti-Aβ antibody was eluted from the chip using a wash with glycine-HCl (pH 2). A control injection containing no amyloid-beta served as a control for baseline subtraction. Sensorgrams demonstrating association and dissociation phases were
25 analyzed to determine K_d and K_a . The affinity (KD) of mouse antibody 10D5 for Aβ 1-40 was determined to be 390 nM, and the affinity of humanized 10D5, prepared essentially as described in Example 1, was determined to be 209 nM. Affinity for Aβ 1-42 was biphasic for both mouse 10D5 and humanized 10D5. For mouse 10D5, the affinities for Aβ 1-42 were 0.57 nM and 4950 nM. Humanized 10D5 had affinities for
30 Aβ 1-42 of 0.19 nM and 1020 nM.

Example 4

Epitope mapping of mouse and humanized 10D5

The BIAcore is an automated biosensor system for measuring molecular interactions [Karlsson R., *et al. J. Immunol. Methods* 145:229-240 (1991)]. The advantage of the BIAcore over other binding assays is that binding of the antigen can be measured without having to label or immobilize the antigen (i.e. the antigen maintains a more native conformation). The BIAcore methodology was used to assess the binding of various amyloid-beta peptide fragments to either mouse 10D5 or humanized 10D5 (prepared substantially as described in Example 1). All dilutions were made with HEPES buffered saline containing Tween 20. A single concentration of a variety of fragments of human A β or mouse A β 1-40 (BioSource International) was used. Human amyloid beta fragments 1-10 and 1-20 bound to mouse 10D5 and to humanized 10D5, while human A β fragments 10-20 and 16-25 did not bind to either antibody. Neither mouse 10D5 nor humanized 10D5 bound mouse A β 1-40. Using this methodology, the binding epitope for both mouse and humanized 10D5 appears to be between amino acids 1 and 10 of human A β .

Example 5

In vivo experiments with 10D5

Unless otherwise stated, all studies used PDAPP mice, and all injections were intraperitoneal (i.p.) In general, a control group of mice received injections of saline. In some cases, another control group received injections of a non-specific mouse IgG preparation.

Six weeks of weekly injection of 360 μ g of 10D5 in old mice (24 month) raised soluble A β_{total} in hippocampus by 16% and A β 1-42 in hippocampus by 21%, while lowering hippocampal insoluble A β_{total} by 24% and A β 1-42 by 26% (no statistically significant difference; 9 animals per control group and 10 animals per antibody group). In the cortex, mean insoluble A β_{total} was lower by 27% and A β 1-42 by 29%, while mean insoluble A β 1-40 increased by 7% (no statistically significant differences).

In hemizygous, 4 month old mice, administration of 360 μ g 10D5 per animal: 1) raised average plasma A β 1-40 and A β 1-42 levels approximately 3-fold by 24 hours after administration; and 2) had no significant effect on soluble A β 1-40 in the cortex after 24

hours compared with saline control (no differences were statistically significant; 5 animals per group).

Administration of 360 μ g of 10D5 per animal (5 animals per group, saline control): 1) raised average plasma A β 1-40 and A β 1-42 levels approximately 14-fold and 19-fold, respectively by 24 hours after administration; 2) had no consistent or significant effect on soluble or insoluble A β 1-40, A β 1-42, or A β_{total} in the cortex or hippocampus after 24 hours; 3) lowered soluble A β 1-40, A β 1-42, and A β_{total} in the cerebellum by 50% ($p < 0.05$), 33%, and 13%, respectively; and 4) lowered insoluble A β 1-40, A β 1-42, and A β_{total} in the cerebellum by 53% ($p < 0.001$), 46% ($p < 0.001$), and 30% ($p < 0.01$), respectively.

In young mice, administration of 360 μ g of 10D5 per animal (5 per group): 1) raised average plasma A β 1-42 levels approximately 33% by 24 hours after administration; and 2) in the cortex, raised soluble A β 1-40 3.4-fold ($p < 0.001$), lowered soluble A β 1-42 by 22% ($p < 0.05$), lowered insoluble A β 1-40 about 10% and increased insoluble A β 1-42 about 12%.

We claim:

1. Humanized 10D5 antibody.

2. A humanized antibody, or fragment thereof, comprising a humanized light chain comprising three light chain complementarity determining regions (CDRs) from the mouse monoclonal antibody 10D5 and a light chain variable region framework sequence from a human immunoglobulin light chain; and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 10D5 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain; wherein the light chain CDRs have the following amino acid sequences:

10 light chain CDR1:
 1 5 10 15
 Arg Ser Ser Gln Ile Ile His Ser Asn Gly Asn Thr Tyr Leu Glu
 (SEQ ID NO:1)

15 light chain CDR2:
 1 5
 Lys Val Ser Asn Arg Phe Ser (SEQ ID NO:2)

light chain CDR3:
 20 1 5
 Phe Gln Gly Ser His Val Pro Leu Thr (SEQ ID NO:3)

and the heavy chain CDRs have the following amino acid sequences:

heavy chain CDR1:
 25 1 5
 Thr Ser Gly Met Gly Val Ser (SEQ ID NO:4)

heavy chain CDR2:
 1 5 10 15
 30 His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser
 (SEQ ID NO:5)

and, heavy chain CDR3:
 1 5 10
 35 Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr (SEQ ID NO:6).

3. A humanized antibody or fragment thereof comprising a humanized light chain variable region having the sequence of SEQ ID NO:7 and a humanized heavy variable region having the sequence of SEQ ID NO:8.

4. The humanized antibody or fragment thereof of claim 3 having a light chain variable region of the sequence given by SEQ ID NO:9 and a heavy chain variable region given by SEQ ID NO:10.

5. The humanized antibody or fragment thereof of claim 3 having a light chain of the sequence given by SEQ ID NO:11 and a heavy chain of the sequence given by SEQ ID NO:12.

6. An antibody fragment obtainable by enzymatic cleavage of the humanized antibody of any one of claims 1 - 5.

7. An Fab or F(ab')₂ fragment of any one of the humanized antibodies of claims 1 - 5.

8. The F(ab')₂ fragment of claim 7.

9. The Fab fragment of claim 7.

10. The humanized antibody or fragment of any one of claims 1 - 9, which is a single chain antibody.

11. The humanized antibody or fragment of any one of claims 1 - 10 that is an IgG₁ immunoglobulin isotype.

12. The humanized antibody or fragment of any one of claims 1 - 11, wherein the antibody or fragment thereof is produced in a host cell selected from the group consisting of a myeloma cell, a chinese hamster ovary cell, a syrian hamster ovary cell, and a human embryonic kidney cell.

13. A polynucleotide compound, comprising a sequence coding for the light chain or the heavy chain of the humanized antibody of any one of claims 1 - 12, or a fragment thereof.

14. A polynucleotide sequence, which when expressed in a suitable host cell, yields an antibody of any one of claims 1 – 12.

15. The polynucleotide of claim 13 or 14 selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 17, and a polynucleotide comprising a sequence that codes
5 for the light chain variable region given by SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11.

16. The polynucleotide of claim 13 or 14 selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, and a polynucleotide comprising a sequence that codes
10 for the heavy chain variable region given by SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12.

17. An expression vector for expressing the antibody of any one of claims 1 - 12 comprising the polynucleotide sequence of any one of claims 13 - 16.

18. A cell transfected with the expression vector of claim 17.

19. A cell transfected with two expression vectors of claim 17, wherein a first
15 vector comprises the polynucleotide sequence coding for the light chain and a second vector comprises the sequence coding for the heavy chain.

20. A cell that is capable of expressing the humanized antibody or fragment of any one of claims 1 – 12.

21. The cell of any one of claims 18 – 20, wherein the cell is selected from the
20 group consisting of a myeloma cell, a chinese hamster ovary cell, a syrian hamster ovary cell, and a human embryonic kidney cell.

22. A pharmaceutical composition comprising the humanized antibody or fragment of any one of claims 1 – 12, and a pharmaceutically acceptable excipient.

23. A method of treating Down's syndrome, clinical or pre-clinical Alzheimer's disease, or clinical or pre-clinical cerebral amyloid angiopathy in a human subject, comprising administering to the human subject an effective amount of a humanized antibody or fragment of any one of claims 1 – 12.

5 24. A method to inhibit the formation of A β plaque in the brain of a human subject, comprising administering to the human subject an effective amount of the humanized antibody or fragment of any one of claims 1 – 12.

25. A method to reduce A β plaque in the brain of a human subject, comprising administering to the human subject an effective amount of a humanized antibody or
10 fragment of any one of claims 1 – 12.

26. The method of either of claims 24 – 25, wherein the subject is diagnosed with clinical or pre-clinical Alzheimer's disease, Down's syndrome, or clinical or pre-clinical cerebral amyloid angiopathy.

27. The method of any one of claims 24 – 25, wherein the subject is not
15 diagnosed with clinical or pre-clinical Alzheimer's disease, Down's syndrome, or clinical or pre-clinical cerebral amyloid angiopathy.

28. Use of the humanized antibody or a fragment thereof according to any one of Claims 1 – 12 for the manufacture of a medicament, including prolonged expression of recombinant sequences of the antibody or antibody fragment in human tissues, for treating
20 clinical or pre-clinical Alzheimer's disease, Down's syndrome, or clinical or pre-clinical cerebral amyloid angiopathy.

29. Use of the humanized antibody or fragment of any one of claims 1 – 12 for the manufacture of a medicament for treating Alzheimer's disease.

SEQUENCE LISTING

<110> Eli Lilly and Company

<120> Humanized Antibodies

<130> X-14819

<150> US 60/287,653

<151> 2001-04-30

<160> 20

<170> PatentIn version 3.1

<210> 1

<211> 16

<212> PRT

<213> mus sp.

<400> 1

Arg Ser Ser Gln Asn Ile Ile His Ser Asn Gly Asn Thr Tyr Leu Glu
1 5 10 15

<210> 2

<211> 7

<212> PRT

<213> mus sp.

<400> 2

Lys Val Ser Asn Arg Phe Ser
1 5

<210> 3

<211> 9

<212> PRT

<213> Mus sp.

<400> 3

Phe Gln Gly Ser His Val Pro Leu Thr
1 5

<210> 4

<211> 7

<212> PRT

<213> Mus sp.

<400> 4

Thr Ser Gly Met Gly Val Ser
1 5

<210> 5

<211> 16

<212> PRT

<213> Mus sp.

<400> 5

His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 6

<211> 13

<212> PRT

<213> Mus sp.

<400> 6

Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr
1 5 10

<210> 7

<211> 113
<212> PRT
<213> humanized antibody

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=Val or Leu

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa=Ser or Thr

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> Xaa=Thr or Ser

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa=Gln, Asp, or Asn

<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> Xaa=Ile or Val

<220>
<221> MISC_FEATURE
<222> (50)..(50)

<223> Xaa=Arg or Lys

<220>

<221> MISC_FEATURE

<222> (88)..(88)

<223> Xaa=Val or Leu

<220>

<221> MISC_FEATURE

<222> (105)..(105)

<223> Xaa=Gly or Ala

<220>

<221> MISC_FEATURE

<222> (109)..(109)

<223> Xaa=Val or Leu

<400> 7

Asp Val Xaa Met Thr Gln Xaa Pro Leu Ser Leu Pro Val Xaa Leu Gly
1 5 10 15

Xaa Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Xaa His Ser
20 25 30

Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Xaa Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Xaa Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95

Ser His Val Pro Leu Thr Phe Gly Xaa Gly Thr Lys Xaa Glu Ile Lys
100 105 110

Arg

<210> 8

<211> 123

<212> PRT

<213> humanized antibody

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa=Gln or Glu

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa=Val or Ala

<220>

<221> MISC_FEATURE

<222> (64)..(64)

<223> Xaa=Ser or Thr

<220>

<221> MISC_FEATURE

<222> (77)..(77)

<223> Xaa=Lys or Arg

<220>

<221> MISC_FEATURE

<222> (78)..(78)

<223> Xaa=Ser or Thr

<220>

<221> MISC_FEATURE

<222> (83)..(83)

<223> Xaa=Thr or Ser

<220>

<221> MISC_FEATURE

<222> (84)..(84)

<223> Xaa=Met, Ile or Leu

<220>

<221> MISC_FEATURE

<222> (86)..(86)

<223> Xaa=Asn, Ser, Thr

<220>

<221> MISC_FEATURE

<222> (87)..(87)

<223> Xaa=Met, Val, or Leu

<220>

<221> MISC_FEATURE

<222> (118)..(118)

<223> Xaa=Leu or Ser

<400> 8

Xaa	Xaa	Thr	Leu	Lys	Glu	Ser	Gly	Pro	Val	Leu	Val	Lys	Pro	Thr	Glu
1				5					10					15	

Thr	Leu	Thr	Leu	Thr	Cys	Thr	Phe	Ser	Gly	Phe	Ser	Leu	Ser	Thr	Ser
			20					25					30		

Gly	Met	Gly	Val	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Ala	Leu	Glu
		35					40					45			

Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Xaa
 50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Xaa Xaa Gln Val
 65 70 75 80

Val Leu Xaa Xaa Thr Xaa Xaa Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 85 90 95

Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Xaa Val Thr Val Ser Ser
 115 120

<210> 9

<211> 113

<212> PRT

<213> humanized antibody

<400> 9

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Ile His Ser
 20 25 30

Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95

Ser His Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

Arg

<210> 10

<211> 123

<212> PRT

<213> humanized antibody

<400> 10

Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30

Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45

Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val
 65 70 75 80

Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 85 90 95

Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 11

<211> 219

<212> PRT

<213> humanized antibody

<400> 11

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Ile His Ser
 20 25 30

9/19

Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95

Ser His Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
 145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 12

<211> 453

<212> PRT

<213> humanized antibody

<400> 12

Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1 5 10 15

10/19

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30

Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45

Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val
 65 70 75 80

Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 85 90 95

Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
 210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 260 265 270

11/19

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 340 345 350

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 370 375 380

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 405 410 415

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 435 440 445

Leu Ser Pro Gly Lys
 450

<210> 13

<211> 46

<212> DNA

<213> DNA primer

<400> 13
 tatagagctc aagcttggat ggtgggaaga tggatacagt tggatgc

46

<210> 14

<211> 50

<212> DNA

<213> DNA primer

<400> 14

tatagagctc aagcttccag tggatagach gatggggstg tygttttggc 50

<210> 15

<211> 1953

<212> DNA

<213> humanized antibody

<400> 15

acgcgtccac catgaagttg cctgttaggc tgttgggtact gatgttctgg attcctgctt 60
ccagcagtga tgttgtgatg acccaatctc cactctccct gcctgtcact cttggacagc 120
cagcctccat ctcttgcaga tctagtcaga acattataca tagtaatgga aacacctatt 180
tagaatggta cctgcagaaa ccaggccagt ctccaaggct cctgatctac aaagtttcca 240
accgattttc tgggggtcca gacaggttca gtggcagtgg atcagggaca gatttcacac 300
tcaagatcag cagagtggag gctgaggatg tgggagtta ttactgcttt caaggttcac 360
atgttccgct cactttcggc ggagggacca aggtggaaat aaaacgtaag tgcactttcc 420
taatctagaa attctaaact ctgagggggg cggatgacgt ggccattctt tgcctaaagc 480
attgagtta ctgcaaggtc agaaaagcat gcaaagccct cagaatggct gcaaagagct 540
ccaacaaaac aatttagaac ttatttaagg aataggggga agctaggaag aaactcaaaa 600
catcaagatt ttaaatacgc ttcttgggtct ccttgctata attatctggg ataagcatgc 660
tgttttctgt ctgtccctaa catgccctgt gattatccgc aaacaacaca cccaagggca 720
gaactttgtt acttaaacac catcctgttt gcttctttcc tcaggaactg tggctgcacc 780
atctgtcttc atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt 840
gtgcctgctg aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc 900
cctccaatcg ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta 960
cagcctcagc agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc 1020
ctgcgaagtc acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga 1080
gtgttagagg gagaagtgcc cccacctgct cctcagttcc agcctgacct cctcccatcc 1140
tttggcctct gacccttttt ccacagggga cctacccta ttgcggtcct ccagctcatc 1200
tttcacctca cccccctcct cctccttggc ttttaattatg ctaatgttgg aggagaatga 1260

ataaataaag tgaatctttg cacctgtggt ttctctcttt cctcatttaa taattattat 1320
 ctgttggtttt accaactact caatttctct tataagggac taaatatgta gtcacccctaa 1380
 ggcgcataac catttataaa aatcatcctt cattctattt taccctatca tcctctgcaa 1440
 gacagtcctc cctcaaacc acaagccttc tgcctcaca gtcccctggg ccatggtagg 1500
 agagacttgc ttcttggtt tcccctctc agcaagccct catagtcctt ttttaagggg 1560
 acaggtctta cagtcataata tcctttgatt caattccctg agaatcaacc aaagcaaatt 1620
 tttcaaaaga agaaacctgc tataaagaga atcattcatt gcaacatgat ataaaataac 1680
 aacacaataa aagcaattaa ataaacaaac aatagggaaa tgtttaagtt catcatggta 1740
 cttagactta atggaatgtc atgccttatt tacattttta aacaggtact gagggactcc 1800
 tgtctgcaa gggccgtatt gagtactttc cacaacctaa tttaatccac actatactgt 1860
 gagattaaaa acattcatta aaatgttgca aaggttctat aaagctgaga gacaaatata 1920
 ttctataact cagcaatccc acttctagga tcc 1953

<210> 16

<211> 3256

<212> DNA

<213> humanized antibody

<400> 16

acgcgtccac catggacagg ctacttcct cattcctgct gctgattgtc cctgcatatg 60
 tcctgtccca gggtactctg aaagagtctg gccctgtact agtgaagccc accgagaccc 120
 tcactctgac ttgtactttc tctgggtttt cactgagcac ttctgggatg ggagttagct 180
 ggattcgtca gcctccagga aaggctctgg agtggctggc acacatttac tgggatgatg 240
 acaagcgcta taacccatcc ctgaagagcc ggctcacaat ctccaaggat acctccaaaa 300
 gccaggtagt cctcacgatg accaatatgg accctgtaga tactgccaca tactactgtg 360
 ttcgaaggcc cattactccg gtactagtcg atgctatgga ctactggggc caaggaaccc 420
 tggtcaccgt ctctcaggt gagtcctcac aacctctaga gctttctggg gcaggccagg 480
 cctgaccttg gctttggggc agggaggggg ctaaggtgag gcaggtggcg ccagccaggt 540
 gcacacccaa tgcccatgag cccagacact ggacgctgaa cctcgcggac agttaagaac 600
 ccaggggcct ctgcgccctg ggcccagctc tgtccacac cgcggtcaca tggcaccacc 660
 tctcttgag cctccacaa gggcccatcg gtcttcccc tggcaccctc ctccaagagc 720
 acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggg 780
 acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 840

cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc 900
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa 960
gttggtgaga ggccagcaca gggagggagg gtgtctgctg gaagccaggc tcagcgctcc 1020
tgcttgacg catcccggct atgcagcccc agtcaggggc agcaaggcag gccccgtctg 1080
cctcttcacc cggaggcctc tgcccgcccc actcatgctc agggagaggg tcttctggct 1140
ttttccccag gctctgggca ggcacaggct aggtgccccct aaccagggcc ctgcacacaa 1200
aggggcaggt gctgggctca gacctgcaa gagccatctc cgggaggacc ctgcccctga 1260
cctaagccca ccccaaaggc caaactctcc actccctcag ctcgacacc ttctctctc 1320
ccagattcca gtaactccca atcttctctc tgcagagccc aaatcttgtg acaaaactca 1380
cacatgccca ccgtgccag gtaagccagc ccaggcctcg cctccagct caaggcggga 1440
caggtgccct agagtagcct gcatccaggg acaggcccca gccgggtgct gacacgtcca 1500
cctccatctc ttctcagca cctgaactcc tggggggacc gtcagtctc ctcttcccc 1560
caaaacccaa ggacaccctc atgatctccc ggaccctga ggtcacatgc gtggtggtg 1620
acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc gtggaggtgc 1680
ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt gtggtcagcg 1740
tcctcacgt cctgcaccag gactggctga atggcaagga gtacaagtgc aaggtctcca 1800
acaaagccct ccagcccc atcgagaaaa ccatctcca agccaaaggt gggacccgtg 1860
gggtgcgagg gccacatgga cagaggccgg ctcgccccc cctctgccct gagagtgacc 1920
gctgtacca cctctgtccc tacagggcag ccccgagaac cacaggtgta caccctgccc 1980
ccatcccggg atgagctgac caagaaccag gtcagcctga cctgcctggc caaaggctc 2040
tatcccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 2100
accacgcctc ccgtgtgga ctccgacggc tcttcttccc tctacagcaa gctcaccgtg 2160
gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 2220
cacaaccact acacgcagaa gagcctctcc ctgtctccgg gtaaagtgt gcgacggccg 2280
gcaagcccc gctccccggg ctctcgcggt cgcacgagga tgcttgccac gtacccccctg 2340
tacatactc cggggcgccc agcatggaaa taaagacccc agcgctgccc tggggccctg 2400
cgagactgtg atggttcttt ccacgggtca ggccgagctt gaggcctgag tggcatgagg 2460
gaggcagagc ggggtccact gtccccacac tggcccaggc tgtgcagggtg tgccctgggccc 2520
gcctaggggtg ggggtcagcc aggggctgcc ctcggcaggg tgggggattt gccagcgtgg 2580
ccctccctcc agcagcacct gccctgggct gggccacggg aagccctagg agccctggg 2640
gacagacaca cagcccctgc ctctgtagga gactgtcctg ttctgtgagc gccctgtcct 2700
ccgacctcca tgccactcg ggggcatgcc tagtccatgt gcgtagggac aggccctccc 2760

```

tcacccatct acccccacgg cactaacccc tggctgccct gccagcctc gcacccgcat 2820
ggggacacaa ccgactccgg ggacatgcac tctcgggccc tgtggaggga ctggtgcaga 2880
tgccacaca cacttcagc ccagaccgt tcaacaaacc ccgactgag gttggccggc 2940
cacacggcca ccacacacac acgtgcacgc ctcacacacg gagcctcacc cgggcgaact 3000
gcacagcacc cagaccagag caaggtcctc gcacacgtga acactcctcg gacacaggcc 3060
cccacgagcc ccacgcggca cctcaaggcc cacgagcctc tcggcagctt ctccacatgc 3120
tgacctgctc agacaaaccc agcctcctc tcacaagggc gccctgcag ccgccacaca 3180
cacacagggg atcacacacc acgtcacgtc cctggccctg gccacttcc cagtgcgcgc 3240
cttcctgca ggatcc 3256

```

<210> 17

<211> 714

<212> DNA

<213> humanized antibody

```

<400> 17
atgaagttgc ctgttaggct gttggtactg atgttctgga ttcctgcttc cagcagtgat 60
gttgtgatga cccaatctcc actctccctg cctgtcactc ttggacagcc agcctccatc 120
tcttgcatga ctatgcagaa cattatacat agtaatggaa acacctatct agaattggtac 180
ctgcagaaac caggccagtc tccaaggctc ctgatctaca aagtttccaa ccgattttct 240
ggggtcccag acaggttcag tggcagtggc tcaggagacag atttcacact caagatcagc 300
agagtggagg ctgaggatgt gggagtttat tactgctttc aaggttcaca tgttccgctc 360
actttcggcg gagggaccaa ggtggaaata aaacgaactg tggctgcacc atctgtcttc 420
atcttccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480
aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540
ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600
agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660
acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgt 714

```

<210> 18

<211> 1416

<212> DNA

<213> humanized antibody

<400> 18
atggacaggc ttacttcctc attcctgctg ctgattgtcc ctgcatatgt cctgtcccag 60
gttactctga aagagtctgg ccctgtacta gtgaagccca ccgagaccct cactctgact 120
tgtactttct ctgggttttc actgagcact tctggtatgg gagtgagctg gattcgtcag 180
cctccaggaa aggcctctgga gtggctggca cacatttact gggatgatga caagcgctat 240
aaccatccc tgaagagccg gctcacaatc tccaaggata cctccaaaag ccaggtagtc 300
ctcacgatga ccaatatgga ccctgtagat actgccacat actactgtgt tcgaaggccc 360
attactccgg tactagtcga tgctatggac tactggggcc aaggaaccct ggtcaccgtc 420
tcctcagcct ccaccaaggg cccatcggtc tccccctgg caccctcctc caagagcacc 480
tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtgacg 540
gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccgcc tgtcctacag 600
tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag ctggggcacc 660
cagacctaca tctgcaacgt gaatcacaag cccagcaaca ccaagggtgga caagaaagtt 720
gagcccaaat cttgtgacaa aactcacaca tgcccaccgt gcccagcacc tgaactcctg 780
gggggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccg 840
acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 900
aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 960
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 1020
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1080
atctccaaag ccaaggggca gccccgagaa ccacagggtgt acaccctgcc cccatcccg 1140
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 1200
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1260
cccgtgctgg actccgacgg ctcttcttct ctctacagca agctcaccgt ggacaagagc 1320
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1380
tacacgcaga agagcctctc cctgtctccg ggtaaa 1416

<210> 19

<211> 238

<212> PRT

<213> humanized antibody

<400> 19

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
1 5 10 15

Ser Ser Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val
20 25 30

Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
35 40 45

Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
50 55 60

Gly Gln Ser Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
65 70 75 80

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys
100 105 110

Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val
115 120 125

Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
130 135 140

Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
145 150 155 160

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
165 170 175

Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190

Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
195 200 205

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
210 215 220

Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

<210> 20

<211> 472

<212> PRT

<213> humanized antibody

<400> 20

Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Ile Val Pro Ala Tyr
 1 5 10 15

Val Leu Ser Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys
 20 25 30

Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu
 35 40 45

Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys
 50 55 60

Ala Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
 65 70 75 80

Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys
 85 90 95

Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala
 100 105 110

Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
 115 120 125

Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
 130 135 140

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
 145 150 155 160

Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
 165 170 175

Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
 180 185 190

His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
 195 200 205

Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
 210 215 220

Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
 225 230 235 240
 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 245 250 255
 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 260 265 270
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 275 280 285
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 290 295 300
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 305 310 315 320
 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 325 330 335
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 340 345 350
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 355 360 365
 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 370 375 380
 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 385 390 395 400
 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 405 410 415
 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 420 425 430
 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 435 440 445
 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 450 455 460
 Ser Leu Ser Leu Ser Pro Gly Lys
 465 470